Literature DB >> 30897321

miR-186-5p Functions as a Tumor Suppressor in Human Osteosarcoma by Targeting FOXK1.

Zhiqiang Zhang1, Wen Zhang2, Junsheng Mao1, Zheng Xu1, Mingyu Fan3.   

Abstract

BACKGROUND/AIMS: Aberrantly expressed miRNAs play a vital role in the development of some cancers, such as human osteosarcoma (OS). However, the detailed molecular mechanisms underlying miR-186-5p-involved osteosarcoma are unclear.
METHODS: qRT-PCR and western blot analysis were employed to measure the expressions of miR-186-5p and forkhead box k1 (FOXK1). CCK-8 assay evaluated the effect of miR-186-5p and FOXK1 on cell proliferation. Transwell assay confirmed cell migration and invasion. Eventually, the dual-luciferase reporter assay validated 3'-untranslated region (3'-UTR) of FOXK1 as a direct target of miR-186-5p.
RESULTS: Down-regulation of miR-186-5p was identified in OS tissues and cell lines, and negatively correlated with distant metastasis, Enneking stage and poor 5-year prognosis as well as the expression of forkhead box k1 (FOXK1) protein. Further assays demonstrated that miR-186-5p overexpression had inhibitory effects on in-vitro cell proliferation, cell cycle, and in-vivo tumor growth. miR-186-5p overexpression also inhibited the epithelial-tomesenchymal transition (EMT), migration and invasion of OS cells. Importantly, miR-186-5p directly targeted FOXK1 3'-UTR and negatively regulated its expression. Silencing of FOXK1 expression enhanced the inhibitory effects of miR-186-5p on OS cell proliferation, migration and invasion.
CONCLUSION: These findings highlighted miR-186-5p as a tumor suppressor in the regulation of progression and metastatic potential of OS, and may benefit the development of therapies targeting miR-186-5p in patients with OS. © Copyright by the Author(s). Published by Cell Physiol Biochem Press.

Entities:  

Keywords:  FOXK1; Osteosarcoma; Suppressor; miR-186-5p

Mesh:

Substances:

Year:  2019        PMID: 30897321     DOI: 10.33594/000000039

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  15 in total

1.  LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathway.

Authors:  Jianwu Long; Longfei Liu; Xuefeng Yang; Xiaojun Zhou; Xianzhou Lu; Lei Qin
Journal:  Hum Cell       Date:  2022-10-15       Impact factor: 4.374

2.  Circ_ROBO2/miR-186-5p/TRIM14 axis regulates oxidized low-density lipoprotein-induced cardiac microvascular endothelial cell injury.

Authors:  Qinghu Ye; Changlin Ju; Zhou Ye; Jiaqiong Tong
Journal:  Regen Ther       Date:  2022-05-10       Impact factor: 3.651

3.  Retracted Article: Long non-coding RNA KCNQ1OT1 regulates cell proliferation, apoptosis and chemo-sensitivity through modulating the miR-186-5p/NCAM1 axis in acute myeloid leukemia cells.

Authors:  Jing Dai; Kai Wang; Tao Liu; Qiong Wang; Yingxu Pang
Journal:  RSC Adv       Date:  2019-11-07       Impact factor: 4.036

4.  The lncRNA-DLEU2/miR-186-5p/PDK3 axis promotes the progress of glioma cells.

Authors:  Zuochang Xie; Xiaojian Li; Hua Chen; Ailiang Zeng; Yan Shi; Yong Tang
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

5.  MicroRNA-186-5p Inhibits Proliferation And Metastasis Of Esophageal Cancer By Mediating HOXA9.

Authors:  Changqin Xu; Bin Li; Shulei Zhao; Bingjie Jin; Ruzhen Jia; Jian Ge; Hongwei Xu
Journal:  Onco Targets Ther       Date:  2019-10-30       Impact factor: 4.147

6.  MicroRNA‑186‑5p downregulation inhibits osteoarthritis development by targeting MAPK1.

Authors:  Qing Li; Mingjie Wu; Guofang Fang; Kuangwen Li; Wengang Cui; Liang Li; Xia Li; Junsheng Wang; Yanhong Cang
Journal:  Mol Med Rep       Date:  2021-02-04       Impact factor: 2.952

Review 7.  microRNAs Mediated Regulation of the Ribosomal Proteins and its Consequences on the Global Translation of Proteins.

Authors:  Abu Musa Md Talimur Reza; Yu-Guo Yuan
Journal:  Cells       Date:  2021-01-08       Impact factor: 6.600

Review 8.  The Dual Role of miR-186 in Cancers: Oncomir Battling With Tumor Suppressor miRNA.

Authors:  Ying Xiang; Qing Tian; Li Guan; Shuai-Shuai Niu
Journal:  Front Oncol       Date:  2020-03-05       Impact factor: 6.244

Review 9.  Osteosarcoma and Metastasis.

Authors:  Gaohong Sheng; Yuan Gao; Yong Yang; Hua Wu
Journal:  Front Oncol       Date:  2021-12-10       Impact factor: 6.244

10.  Repression of lncRNA PART1 attenuates ovarian cancer cell viability, migration and invasion through the miR-503-5p/FOXK1 axis.

Authors:  Bing Li; Ge Lou; Jiahui Zhang; Ning Cao; Xi Yu
Journal:  BMC Cancer       Date:  2022-01-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.